New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Specialised Therapeutics (ST) said Minjuvi (tafasitamab) plus rituximab and lenalidomide has been listed on Australia’s PBS for adults with relapsed or refractory follicular lymphoma (Grade 1-3a), effective 1 Aug 2026. ST cites Phase 3 inMIND results showing a 57% lower risk of progression, relapse or death vs placebo plus lenalidomide and rituximab. Incyte (NASDAQ:INCY) holds an exclusive distribution deal.
How this was made
The 30-second read
Why it matters
The key new fact is the PBS listing effective 1 August 2026, following TGA registration in April 2026, which should improve subsidized access for eligible patients and can translate into incremental demand for the partnered product.
Market read
A new PBS reimbursement decision for a specific lymphoma regimen is a tangible commercialization catalyst, but the article provides no financial quantification.
What to watch
The release lacks pricing, reimbursement level, expected patient volumes, and any incremental sales forecast, limiting near-term earnings impact visibility.
Background
Minjuvi (tafasitamab) plus rituximab and lenalidomide is described as the first chemotherapy-free CD19 and CD20 dual-targeted regimen listed on Australia’s PBS for adults with relapsed or refractory follicular lymphoma (Grade 1-3a).
Ticker impact
Incyte’s exclusive distribution agreement is cited as the commercial backbone for Minjuvi, now PBS-listed in Australia for R/R follicular lymphoma.
Moderate positive bias for INCY on reimbursement-driven demand expectations, though magnitude is likely limited versus global revenue base.
The article is a product reimbursement milestone tied to Incyte’s distribution rights, but it provides no financial terms, uptake, or guidance.
Market effects
Reimbursement approval for a chemotherapy-free CD19/CD20 immunotherapy combo may strengthen sentiment around next-gen lymphoma immunotherapy regimens.
Improves access in Australia for relapsed/refractory follicular lymphoma, potentially accelerating local adoption versus non-funded alternatives.
Adds to the international reimbursement footprint for tafasitamab-based regimens, supporting broader commercialization momentum.
Counterpoint
PBS listing does not guarantee rapid uptake; real-world prescribing may be constrained by eligibility criteria, clinician preference, and competing regimens.
Key entities
- drugMinjuvi (tafasitamab)
Chemotherapy-free CD19-targeting immunotherapy used with rituximab and lenalidomide for R/R follicular lymphoma (Grade 1-3a) on Australia’s PBS.
- companySpecialised Therapeutics (ST)
Announces the PBS listing and describes its distribution partnership role for Minjuvi in Australia, New Zealand, and Singapore.
- companyIncyte
Named as the partner under an exclusive distribution agreement for Minjuvi, now benefiting from PBS reimbursement in Australia.
- regulatorTGA
Approved Minjuvi for R/R follicular lymphoma via Project Orbis in April 2026, preceding the PBS listing.
